| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Cash provided by financing activities | 492 | 479 |
| Net decrease in cash, cash equivalents and restricted cash | -22,754 | -15,988 |
| Cash and cash equivalents at beginning of period | 30,711 | - |
| Cash and cash equivalents at end of period | 7,957 | - |
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)